RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oyster Point Pharma Stock

Oyster Point Pharma Liabilities 2024

Oyster Point Pharma Liabilities

123.08 M USD

Ticker

OYST

ISIN

US69242L1061

WKN

A2PTTE

In 2024, Oyster Point Pharma's total liabilities amounted to 123.08 M USD, a 0% difference from the 0 USD total liabilities in the previous year.

Oyster Point Pharma Aktienanalyse

What does Oyster Point Pharma do?

Oyster Point Pharma Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. The company is headquartered in the San Francisco Bay Area and was founded in 2015. History: Oyster Point Pharma was founded by an experienced team of biologists and pharmaceutical experts. The company was supported by venture capital financing from leading venture capitalists. The founders' goal was to develop innovative therapies for eye diseases. In 2017, the company introduced a pipeline of therapies for various eye diseases based on the stimulation of tear flow, corneal nerves, and neurons. Since then, the company has expanded its pipeline and continues to invest significantly in the research and development of innovative therapies. Business model: Oyster Point Pharma has developed an innovative business model based on the development of therapies for eye diseases. The company utilizes its proprietary technology platform to identify new molecular targets and develop effective therapeutic options. The company works closely with leading scientists and clinics to develop and validate its pipeline of therapies. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Segments: Oyster Point Pharma focuses on developing innovative therapies for eye diseases. The company currently has three main products in its pipeline: OC-01, OC-02, and OC-03. OC-01 is a nasal spray based on the stimulation of tear flow. The product is currently in phase 3 clinical development for the treatment of patients with dry eye. Treatment with OC-01 is intended to increase the production and flow of tear fluid, thus relieving symptoms such as dryness, itching, and pain. OC-02 is a gel based on the stimulation of corneal nerves. The product is currently in phase 2 clinical development for the treatment of patients with neurotrophic keratitis. Treatment with OC-02 is intended to promote the regeneration of corneal nerves and accelerate the healing of the cornea. OC-03 is a nasal spray based on the stimulation of neurons in the nasal and oral areas. The product is currently in the preclinical development phase for the treatment of patients with acute glaucoma and has not yet been approved for use in humans. Products: Oyster Point Pharma currently has three main products in its pipeline: OC-01, OC-02, and OC-03. These products aim to develop innovative therapies for various eye diseases. The products utilize proprietary technologies to selectively stimulate tear flow, corneal nerves, and neurons. By developing these innovative therapies, the company aims to improve the vision and quality of life of patients. Summary: Oyster Point Pharma is an innovative biopharmaceutical company focused on the development of therapies for eye diseases. The company has developed a proprietary technology platform for the identification of new molecular targets and the development of effective therapeutic options. The company currently has three main products in its pipeline, aiming to develop innovative therapies for various eye diseases. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Oyster Point Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Oyster Point Pharma's Liabilities

Oyster Point Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Oyster Point Pharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Oyster Point Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Oyster Point Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Oyster Point Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Oyster Point Pharma stock

What is the level of liabilities of Oyster Point Pharma this year?

Oyster Point Pharma has a debt balance of 123.08 M USD this year.

What were the liabilities of Oyster Point Pharma compared to the previous year?

The liabilities of Oyster Point Pharma have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Oyster Point Pharma?

High liabilities can pose a risk for investors of Oyster Point Pharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Oyster Point Pharma?

Low liabilities mean that Oyster Point Pharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Oyster Point Pharma affect the company?

An increase in liabilities of Oyster Point Pharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Oyster Point Pharma affect the company?

A decrease in the liabilities of Oyster Point Pharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Oyster Point Pharma?

Some factors that can influence the liabilities of Oyster Point Pharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Oyster Point Pharma so important for investors?

The liabilities of Oyster Point Pharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Oyster Point Pharma take to modify the liabilities?

To change its liabilities, Oyster Point Pharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Oyster Point Pharma pay?

Over the past 12 months, Oyster Point Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oyster Point Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Oyster Point Pharma?

The current dividend yield of Oyster Point Pharma is .

When does Oyster Point Pharma pay dividends?

Oyster Point Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oyster Point Pharma?

Oyster Point Pharma paid dividends every year for the past 0 years.

What is the dividend of Oyster Point Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oyster Point Pharma located?

Oyster Point Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oyster Point Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oyster Point Pharma from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Oyster Point Pharma pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Oyster Point Pharma in the year 2023?

In the year 2023, Oyster Point Pharma distributed 0 USD as dividends.

In which currency does Oyster Point Pharma pay out the dividend?

The dividends of Oyster Point Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oyster Point Pharma

Our stock analysis for Oyster Point Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oyster Point Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.